ARTICLE | Clinical News

Reminyl galantamine: Phase III data; marketed in Europe, approvable in U.S. and under review in Canada

December 11, 2000 8:00 AM UTC

SHP and partner Janssen Pharmaceutica (Beerse, Belgium) published in the British Medical Journal previously reported results of a 653-patient international Phase III trial, showing that 24 or 32 mg/da...